Efficacy and Safety of Dulaglutide Biosimilar <scp>LY05008</scp> Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study
Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study
Baiping Sun, Lixin Guo, Junling Gu, Shunbin Li et al.
Citations
1 citations
Journal
Journal of Diabetes
Topics
Diabetes Treatment and Management
Field-Weighted Citation Impact (FWCI)
1.29
article
Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open‐Label, Active Comparator Study
Baiping Sun, Lixin Guo, Junling Gu, Shunbin Li, Changlin Dou, Zhaoyang Zeng, Liujun Fu, Shu Li, Li Liu, Zhifeng Cheng, Lili Zhang, Shuguang Pang, Yanyan Zhao, Qifu Li, Jie Shen, Fang Bian, Lianwei Wang
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of DiabetesVol. 17(4)
Institutions
Harbin Medical University (CN), Zhumadian Central Hospital (CN), The First People's Hospital of Shunde (CN), Huzhou Central Hospital (CN), Jinan Central Hospital (CN), People's Hospital of Cangzhou (CN), Beijing Hospital (CN), Fourth Affiliated Hospital of Harbin Medical University (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Shanxi Jincheng Anthracite Mining Group (China) (CN), First Affiliated Hospital of Henan University of Science and Technology (CN), Huizhou Central People's Hospital (CN), Yichang Central People's Hospital (CN), Second People’s Hospital of Yibin (CN), Southern Medical University (CN), Chongqing Medical University (CN)